Norbert Kraut

10.8k citations

72 papers · 7.2k indexed · 5 hit papers · h-index 33

Impact in

Cell Biology top 0.5%
- Microtubule and mitosis dynamics
Oncology top 0.5%
- Cancer Cells and Metastasis
- Cancer-related Molecular Pathways

Papers in

Cancer Research 18
- NF-κB Signaling Pathways 6
Oncology 31
- Cancer-related Molecular Pathways 9
- Cancer Cells and Metastasis 6

Co-authors: Hartmut Beug Margit A. Huber Stefan Grünert Mark Petronczki Thomas Wirth Hubert Pehamberger Ninel Azoitei Bernd Baumann
Journals: Cancer Research (12 papers)Molecular Cancer Therapeutics (9 papers)European Journal of Cancer (3 papers)Journal of Pharmacology and Experimental Therapeutics (3 papers)EMBO Molecular Medicine (2 papers)
Partner nations: Austria Germany United States

In The Last Decade

Norbert Kraut

69 papers receiving 7.1k citations

Hit Papers

5 papers align trajectories log scale

The Small-Molecule Inhibitor BI 2536 Reveals Novel Insights into Mitotic Roles of Polo-like Kinase 1 2007 · 563 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2007 Current Biology
2007 Current Biology
2005 Current Opinion in Cell Biology
2004 Journal of Clinical Investigation
2004 Journal of Clinical Investigation

Peers

Countries citing papers authored by Norbert Kraut

Since Specialization

Citations

This map shows the geographic impact of Norbert Kraut's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Norbert Kraut with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Norbert Kraut more than expected).

Fields of papers citing papers by Norbert Kraut

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Norbert Kraut. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Norbert Kraut. The network helps show where Norbert Kraut may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Norbert Kraut, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Norbert Kraut Line = papers co-authored together Norbert Kraut links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Pharmacodynamic and Antitumor Activity of BI 836880, a Dual Vascular Endothelial Growth Factor and Angiopoietin 2 Inhibitor, Alone and Combined with Programmed Cell Death Protein-1 Inhibition Journal of Pharmacology and Experimental Therapeutics ·Irmgard Hofmann, Anke Baum, Marco H. Hofmann, Francesca Trapani, Sijia Qi, Amjad Mohammed Albanna, Martin Aichinger, Florian Ebner, Julia Kylmälä, Norbert Schweifer, Martina M. Sykora, Erik Depla, Daniel Alejandro Bustamante Lopez, Andreas R. Gschwind, Norbert Kraut, Frank Hilberg, Klaus‐Peter Künkele	2022	9
2	Targeting Son of Sevenless 1: The pacemaker of KRAS Current Opinion in Chemical Biology ·Dirk Kessler, Daniel Gerlach, Norbert Kraut, Darryl B. McConnell	2021	67
3	Antitumor Activity of the IGF-1/IGF-2–Neutralizing Antibody Xentuzumab (BI 836845) in Combination with Enzalutamide in Prostate Cancer Models Molecular Cancer Therapeutics ·Ulrike Weyer-Czernilofsky, Marco H. Hofmann, Katrin Friedbichler, Lena Al-Hilfi, Paul J. Adam, Flavio Solca, Norbert Kraut, Holly M. Nguyen, Eva Corey, Gang Liu, Cynthia C.T. Sprenger, Stephen R. Plymate, Thomas Bogenrieder	2020	14
4	Selective Tumor Cell Apoptosis and Tumor Regression in CDH17-Positive Colorectal Cancer Models using BI 905711, a Novel Liver-Sparing TRAILR2 Agonist Molecular Cancer Therapeutics ·Juan Manuel García‐Martínez, Shirley Wang, Ruotong Zhao, Andreas Wernitznig, Paolo Chetta, Catarina Pinto, Jason Ho, Darrin Dutcher, Min-Jee Oh, Rachel Kroe‐Barrett, Joerg Rinnenthal, Craig Giragossian, 義行武内, Iñigo Tirapu, Frank Hilberg, Norbert Kraut, Mark Pearson, Phornrat Tiranant	2020	23
5	Werner syndrome helicase is a selective vulnerability of microsatellite instability-high tumor cells eLife ·Simone Lieb, H.M. Mehendale, Prashanth Shetty, S.S. Bhadgaonkar, V. D. Perebeinos, Katharina Ehrenhöfer-Wölfer, Andreas Schlattl, Andreas Wernitznig, Jesse Lipp, Kota Nagasaka, Petra van der Lelij, Gerd Bader, Minoru Koi, Ajay Goel, Ralph A. Neumüller, Jan‐Michael Peters, Norbert Kraut, Mark Pearson, Mark Petronczki, Simon Wöhrle	2019	91
6	The FAK inhibitor BI 853520 exerts anti-tumor effects in breast cancer Oncogenesis ·Stefanie Tiede, Nathalie Meyer‐Schaller, Ravi Kiran Reddy Kalathur, Robert Ivánek, Ernesta Fagiani, Isidore Starr, Zhongfeng Xu, E. Liu, Norbert Kraut, Norbert Schweifer, Irene C. Waizenegger, Ruben Bill, Gerhard Christofori	2018	57
7	The IGF1R/INSR Inhibitor BI 885578 Selectively Inhibits Growth of IGF2-Overexpressing Colorectal Cancer Tumors and Potentiates the Efficacy of Anti-VEGF Therapy Molecular Cancer Therapeutics ·Michael P. Sanderson, Marco H. Hofmann, Pilar Garin‐Chesa, Norbert Schweifer, Andreas Wernitznig, Stefan Fischer, Maria Eduarda Montibeller, D. Judkins, Jürgen Moll, Peter Traunmüller, Heribert Arnhof, Ulrike Weyer-Czernilofsky, Stephan K. Zahn, Günther R. Adolf, Norbert Kraut	2017	22
8	Pharmacological Profile of BI 847325, an Orally Bioavailable, ATP-Competitive Inhibitor of MEK and Aurora Kinases Molecular Cancer Therapeutics ·Patrizia Sini, Ulrich Gürtler, Stephan K. Zahn, Christoph Baumann, Dorothea Rudolph, Lena Al-Hilfi, D. Przybylski, Christian Haslinger, Ulrike Tontsch-Grunt, Irene C. Waizenegger, Flavio Solca, Gerd Bader, Andreas Zoephel, Matthias Treu, Ulrich Reiser, Pilar Garin‐Chesa, Guido Boehmelt, Norbert Kraut, Jens Quant, Günther R. Adolf	2016	28
9	A Novel RAF Kinase Inhibitor with DFG-Out–Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation Molecular Cancer Therapeutics ·Irene C. Waizenegger, Anke Baum, Steffen Steurer, Heinz Stadtmüller, Gerd Bader, Otmar Schaaf, Pilar Garin‐Chesa, Andreas Schlattl, Norbert Schweifer, Christian Haslinger, Florian Colbatzky, Krzysztof Fura, Arno Kalkuhl, Norbert Kraut, Günther R. Adolf	2016	68
10	BI 885578, a Novel IGF1R/INSR Tyrosine Kinase Inhibitor with Pharmacokinetic Properties That Dissociate Antitumor Efficacy and Perturbation of Glucose Homeostasis Molecular Cancer Therapeutics ·Michael P. Sanderson, Joshua F. Apgar, Pilar Garin‐Chesa, Marco H. Hofmann, Dirk Kessler, Jens Quant, Alexander Savchenko, Otmar Schaaf, Matthias Treu, Heather Tye, Stephan K. Zahn, Andreas Zoephel, Eric Haaksma, Günther R. Adolf, Norbert Kraut	2015	16
11	Quantitative Phospho-proteomics to Investigate the Polo-like Kinase 1-Dependent Phospho-proteome Molecular & Cellular Proteomics ·翁云骞, Björn Hegemann, Maria Novatchkova, Jonathan Rameseder, Brian A. Joughin, Otto Hudecz, Elisabeth Roitinger, Peter Pichler, Norbert Kraut, Michael B. Yaffe, Jan‐Michael Peters, Karl Mechtler	2011	64
12	BI 5700, a Selective Chemical Inhibitor of I B Kinase 2, Specifically Suppresses Epithelial-Mesenchymal Transition and Metastasis in Mouse Models of Tumor Progression Genes & Cancer ·Margit A. Huber, Helena J. Maier, 実日下部, Ali Akbar, Tahise M. de Oliveira, Guido Boehmelt, Jeffrey B. Madwed, Erick R. R. Young, Daniel R. Marshall, Hubert Pehamberger, Thomas Wirth, Norbert Kraut, Hartmut Beug	2010	15
13	Polo-like Kinase 1 Triggers the Initiation of Cytokinesis in Human Cells by Promoting Recruitment of the RhoGEF Ect2 to the Central Spindle Developmental Cell ·Mark Petronczki, Michael Glotzer, Norbert Kraut, Jan‐Michael Peters	2007	242
14	Proteomic and functional alterations in brain mitochondria from Tg2576 mice occur before amyloid plaque deposition PROTEOMICS ·Frank Gillardon, Wolfgang Rist, Lothar Kußmaul, Johannes Vogel, Matthias Berg, Karin M. Danzer, Norbert Kraut, Bastian Hengerer	2007	118
15	BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo Current Biology ·Martin Steegmaier, Matthias Hoffmann, Anke Baum, Péter Lénárt, Mark Petronczki, Martin Krššák, Ulrich Gürtler, Pilar Garin‐Chesa, Simone Lieb, Jens Quant, Matthias Grauert, Günther R. Adolf, Norbert Kraut, Jan‐Michael Peters, Wolfgang J. Rettig Hit paper breakdown →	2007	691
16	Laser Capture Microdissection of Epithelial Cancers Guided by Antibodies Against Fibroblast Activation Protein and Endosialin Diagnostic Molecular Pathology ·Christian Rupp, Helmut Dolznig, Christina Puri, Norbert Schweifer, Wolfgang Sommergruber, Norbert Kraut, Wolfgang J. Rettig, Dontscho Kerjaschki, Pilar Garin‐Chesa	2006	28
17	Characterization of cancer stroma markers: in silico analysis of an mRNA expression database for fibroblast activation protein and endosialin. PubMed ·Helmut Dolznig, Norbert Schweifer, Christina Puri, Norbert Kraut, Wolfgang J. Rettig, Dontscho Kerjaschki, Pilar Garin‐Chesa	2005	123
18	NF-κB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression Journal of Clinical Investigation ·Margit A. Huber, Ninel Azoitei, Bernd Baumann, Stefan Grünert, Andreas Sommer, Hubert Pehamberger, Norbert Kraut, Hartmut Beug, Thomas Wirth Hit paper breakdown →	2004	734
19	Vitamin D3 enhances the expression of I-mfa, an inhibitor of the MyoD family, in osteoblasts Biochimica et Biophysica Acta (BBA) - Molecular Cell Research ·Kunikazu Tsuji, Norbert Kraut, Mark Groudine, Masaki Noda	2001	10
20	I-mf, a Novel Myogenic Repressor, Interacts with Members of the MyoD Family Cell ·Adeline Yong, Norbert Kraut, Mark Groudine, Harold Weintraub	1996	126

About Norbert Kraut

Norbert Kraut is a scholar working on Cancer Research, Oncology, Molecular Biology, Cell Biology and Pathology and Forensic Medicine, having authored 72 papers that have together received 7.2k indexed citations. Recurring topics across this work include Cancer-related Molecular Pathways (9 papers), Protein Degradation and Inhibitors (9 papers), Microtubule and mitosis dynamics (7 papers), Ubiquitin and proteasome pathways (7 papers), Cancer Cells and Metastasis (6 papers), Genomics and Chromatin Dynamics (6 papers), Genetic factors in colorectal cancer (6 papers) and NF-κB Signaling Pathways (6 papers). The work is most often cited by research in Cell Biology (1.7k citations), Oncology (2.7k citations), Cancer Research (1.4k citations), Molecular Biology (5.0k citations) and Immunology and Allergy (272 citations). Norbert Kraut has collaborated with scholars based in Austria, Germany and United States. Frequent co-authors include Hartmut Beug, Margit A. Huber, Stefan Grünert, Mark Petronczki, Thomas Wirth, Hubert Pehamberger, Ninel Azoitei, Bernd Baumann, Andreas Sommer and Jan‐Michael Peters. Their work appears in journals such as Cancer Research, Molecular Cancer Therapeutics, European Journal of Cancer, Journal of Pharmacology and Experimental Therapeutics and EMBO Molecular Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact